RudaCure Inc. (CEO Yongho Kim), una empresa global de terapéuticos del dolor, anunció el 11th that it will present its next-generation tratamiento del dolor pipeline investigación resultados at the Society for Neuroscience (SfN) Annual Meeting in San Diego, USA on the 19th.
A través de esto presentación, RudaCure will disclose datos preclínicos on its dual-target candidato a nuevo fármaco that simultaneously modulates TRPV1 and MOR (Mu Opioid Receptor).
Según RudaCure, the candidato demostró excellent eficacia analgésica in various dolor neuropático animal models including neuropatía periférica diabética (DPN) and neuropatía periférica inducida por quimioterapia (CIPN). In the osteoartritis (OA) model, it showed not only alivio del dolor but also tissue damage inhibition and cartilage protective effects.
RudaCure enfatizó that this candidato overcomes the fever efectos secundarios commonly reported with TRPV1-class drugs and the addiction/tolerance issues of MOR agonists, achieving both eficacia and seguridad. La empresa está acelerando IND-enabling studies for Phase 1 ensayo clínicos based on these resultados.
El CEO Yongho Kim declaró: "We will present the innovador potential of our next-generation tratamiento del dolor at the world's largest neuroscience conferencia," adding, "We plan to actively advance asociación globals based on RCI002's differentiated mecanismo de acción."
